BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28548087)

  • 21. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma.
    Zhao GY; Lin ZW; Lu CL; Gu J; Yuan YF; Xu FK; Liu RH; Ge D; Ding JY
    Tumour Biol; 2015 Mar; 36(3):1721-9. PubMed ID: 25519684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
    Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
    Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung.
    Sakai Y; Nakai T; Ohbayashi C; Imagawa N; Yanagita E; Satake R; Nitta A; Kajimoto K; Sakuma T; Itoh T
    Int J Surg Pathol; 2013 Oct; 21(5):476-82. PubMed ID: 23794492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.
    Berta J; Kenessey I; Dobos J; Tovari J; Klepetko W; Jan Ankersmit H; Hegedus B; Renyi-Vamos F; Varga J; Lorincz Z; Paku S; Ostoros G; Rozsas A; Timar J; Dome B
    J Thorac Oncol; 2010 Aug; 5(8):1120-9. PubMed ID: 20581707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.
    Malkoski SP; Haeger SM; Cleaver TG; Rodriguez KJ; Li H; Lu SL; Feser WJ; Barón AE; Merrick D; Lighthall JG; Ijichi H; Franklin W; Wang XJ
    Clin Cancer Res; 2012 Apr; 18(8):2173-83. PubMed ID: 22399565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
    Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
    Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
    Kang MW; Lee ES; Yoon SY; Jo J; Lee J; Kim HK; Choi YS; Kim K; Shim YM; Kim J; Kim H
    J Int Med Res; 2011; 39(1):78-85. PubMed ID: 21672310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
    Pikor LA; Ramnarine VR; Lam S; Lam WL
    Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
    Ito R; Iwano S; Kishimoto M; Ito S; Kato K; Naganawa S
    Ann Nucl Med; 2015 Dec; 29(10):897-905. PubMed ID: 26342592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.
    Solomides CC; Evans BJ; Navenot JM; Vadigepalli R; Peiper SC; Wang ZX
    Acta Cytol; 2012; 56(6):645-54. PubMed ID: 23207443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.
    Zhou X; Chen R; Xie W; Ni Y; Liu J; Huang G
    J Nucl Med; 2014 Nov; 55(11):1766-71. PubMed ID: 25342384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome analysis of (18)F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction.
    Ohtaka K; Hida Y; Kaga K; Okamoto S; Shiga T; Tamaki N; Muto J; Nakada-Kubota R; Hirano S; Matsui Y
    Anticancer Res; 2013 Nov; 33(11):5193-8. PubMed ID: 24222169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
    van Baardwijk A; Dooms C; van Suylen RJ; Verbeken E; Hochstenbag M; Dehing-Oberije C; Rupa D; Pastorekova S; Stroobants S; Buell U; Lambin P; Vansteenkiste J; De Ruysscher D
    Eur J Cancer; 2007 Jun; 43(9):1392-8. PubMed ID: 17512190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells.
    Mi YJ; Geng GJ; Zou ZZ; Gao J; Luo XY; Liu Y; Li N; Li CL; Chen YQ; Yu XY; Jiang J
    PLoS One; 2015; 10(3):e0120426. PubMed ID: 25799586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.
    Micke P; Edlund K; Holmberg L; Kultima HG; Mansouri L; Ekman S; Bergqvist M; Scheibenflug L; Lamberg K; Myrdal G; Berglund A; Andersson A; Lambe M; Nyberg F; Thomas A; Isaksson A; Botling J
    J Thorac Oncol; 2011 Nov; 6(11):1833-40. PubMed ID: 22011649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
    Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.